WO1993011744A1 - Medicaments - Google Patents

Medicaments Download PDF

Info

Publication number
WO1993011744A1
WO1993011744A1 PCT/EP1992/002809 EP9202809W WO9311744A1 WO 1993011744 A1 WO1993011744 A1 WO 1993011744A1 EP 9202809 W EP9202809 W EP 9202809W WO 9311744 A1 WO9311744 A1 WO 9311744A1
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
formulation
particulate
acceptable salt
physiologically acceptable
Prior art date
Application number
PCT/EP1992/002809
Other languages
French (fr)
Inventor
Rachel Ann Akehurst
Anthony James Taylor
David Andrew Wyatt
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26299997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1993011744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919126405A external-priority patent/GB9126405D0/en
Priority claimed from GB929202522A external-priority patent/GB9202522D0/en
Priority to DK92924668T priority Critical patent/DK0616524T3/en
Priority to EP92924668A priority patent/EP0616524B1/en
Priority to CA002125666A priority patent/CA2125666C/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to DE69227257T priority patent/DE69227257T2/en
Priority to JP5510574A priority patent/JP3026841B2/en
Priority to AU30851/92A priority patent/AU663905B2/en
Priority to DK04007494T priority patent/DK1440686T3/en
Publication of WO1993011744A1 publication Critical patent/WO1993011744A1/en
Priority to US11/124,086 priority patent/US20050207991A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • This invention relates to aerosol formulations of use for the administration of medicaments by inhalation.
  • aerosols to administer medicaments has been known for several decades.
  • Such aerosols generally comprise the medicament, one or more chlorofluorocarbon propellants and either a surfactant or a solvent, such as ethanoi.
  • the most commonly used aerosol propellants for medicaments have been propellant 1 1 (CC1 3 F) and/or propellant 1 14 (CF 2 C1CF : C1) with propellant 12 (CC1,F 2 ).
  • propellants are now believed to provoke the degradation of stratospheric ozone and there is thus a need to provide aerosol formulations for medicaments which employ so called "ozone-friendly" propellants.
  • a class of propellants which are believed to have minimal ozone-depleting effects in comparison to conventional chlorofluorocarbons comprise fluorocarbons and hydrogen ⁇ containing chlorofluorocarbons, and a number of medicinal aerosol formulations using such propellant systems are disclosed in, for example, EP 0372777, WO91/0401 1, WO91/11 173, WO91/1 1495 and WO91/14422.
  • These applications are all concerned with the preparation of pressurised aerosols for the administration of medicaments and seek to overcome the problems associated with the use of the new class of propellants, in particular the problems of stability associated with the pharmaceutical formulations prepared.
  • EP 0372777 requires the use of 1 , 1 , 1 ,2-tetrafluoroethane in combination with both a cosolvent having greater polarity than 1, 1, 1,2-tetrafluoroethane
  • WO91/04011 discloses medicinal aerosol formulations in which the particulate medicaments are pre-coated with surfactant prior to dispersal in 1, 1, 1,2-tetrafluoroethane-
  • a pharmaceutical aerosol formulation which comprises particulate medicament and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant and with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof.
  • substantially free of surfactant is meant formulations which contain no significant amounts of surfactant, for example less than 0.0001% by weight of the medicament.
  • the particle size of the particulate e.g.
  • micronised medicament should be such as to permit inhalation of substantially all of the medicament into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and preferably in the range 1-10 microns, e.g. 1-5 microns.
  • Medicaments which may be administered in aerosol formulations according to the invention include any drug useful in inhalation therapy which may be presented in a form which is substantially completely insoluble in the selected propellant.
  • Appropriate medicaments may thus be selected from, for example, analgesics, e.g. codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; anti-infectives, e.g.
  • cephalosporins penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine
  • antihistamines e.g. methapyrilene
  • anti-inflammatories e.g. flunisolide, budesonide, tipredane or triamcinolone acetonide
  • antitussives e.g. noscapine
  • bronchodilators e.g.
  • ephedrine adrenaline
  • fenoterol formoterol
  • isoprenaline metaproterenol
  • phenylephrine phenylpropanolamine
  • pirbuterol reproterol
  • rimiterol terbutaline
  • isoetharine isoetharine
  • the medicaments may be used in the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.
  • Particularly preferred medicaments for administration using aerosol formulations in accordance with the invention include anti-allergies, bronchodilators and anti-inflammatory steroids of use in the treatment of respiratory disorders such as asthma by inhalation therapy, for example cromoglycate (e.g. the sodium salt), terbutaline (e.g.
  • reproterol e.g. the hydrochloride salt
  • reproterol e.g. the hydrochloride salt
  • the aerosol formulations according to the invention may , if desired, contain a combination of two or more active ingredients. Aerosol compositions containing two active ingredients (in a conventional propellant system) are known, for example, for the treatment of respiratory disorders such 0 as asthma. Accordingly the present invention further provides aerosol formulations in accordance with the invention which contain two or more particulate medicaments. Medicaments may be selected from suitable combinations of the medicaments mentioned hereinbefore.
  • suitable combinations of bronchodilatory agents include ephedrine 5 and theophylline, fenoterol and ipratropium, and isoetharine and phenylephrine aerosol formulations-
  • Preferred aerosol formulations in accordance with the invention comprise (a) an effective amount of a particulate bronchodilatory medicament (b) an effective amount of a particulate antiinflammatory, preferably a steroidal antiinflammatory medicament and (c) a 10 fluorocarbon or hydrogen - containing chlorofluorocarbon propellant with the proviso that said medicaments are other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof.
  • aerosol formulations may contain a bronchodilator such as isoprenaline in combination with an antiallergic such as cromoglycate (e.g. the sodium salt). '15 Combinations of isoprenaline and sodium cromoglycate are especially preferred.
  • the final aerosol formulation desirably contains 0.005-10% w/w, preferably 0.005-5% w/w, especially 0-01-l.O% w/w, of medicament relative to the total weight of the formulation.
  • the propellants for use in the invention may be any fluorocarbon or 20 hydrogen-containing chlorofluorocarbon or mixtures thereof having a sufficient vapour pressure to render them effective as propellants.
  • the propellant will be a non-solvent for the medicament.
  • Suitable propellants include, for example, C w hydrogen-containing chlorofluorocarbons such as CH 2 C1F, CC1F 2 CHC1F, CF 3 CHCIF, CHF,CCIF,, CHC1FCHF,, CF 3 CH,C1 and CC1F 2 CH 3 ; C hydrogen-containing 5 fluorocarbons such as CHF 2 CHF 2 , CF 3 CFL,F, CHF 2 CH 3 and CF 3 CHFCF 3 ; and perfluorocarbons such as CF 3 CF 3 and CF 3 CF 2 CF 3 .
  • mixtures of the fluorocarbons or hydrogen-containing chlorofluorocarbons may be mixtures of the above identified compounds or mixtures, preferably binary mixtures, with other fluorocarbons or hydrogen-containing 0 chlorofluorocarbons for example CHC1F,, CH-.F, and CF 3 CFL-.
  • a single fluorocarbon or hydrogen-containing chlorofluorocarbon is employed as the propellant.
  • Particularly preferred as propellants are C M hydrogen-containing fluorocarbons such as 1,1, 1,2-tetrafluoroethane (CF 3 CH 2 F) and 1, 1, 1, 2,3,3, 3-heptafluoro-n-propane (CF 3 CHFCF 3 ).
  • the formulations of the invention contain no components which may provoke the degradation of stratospheric ozone.
  • the formulations are substantially free of chlorofluorocarbons such as CC1 3 F, CC1 2 F and CF 3 CC1 3 .
  • the propellant may additionally contain a volatile adjuvant such as a saturated hydrocarbon for example propane, n-butane, isobutane, pentane and isopentane or a dialkyl ether for example dimethyl ether.
  • a volatile adjuvant such as a saturated hydrocarbon for example propane, n-butane, isobutane, pentane and isopentane or a dialkyl ether for example dimethyl ether.
  • a volatile adjuvant such as a saturated hydrocarbon for example propane, n-butane, isobutane, pentane and isopentane or a dialkyl ether for example dimethyl ether.
  • up to 50% w/w of the propellant may comprise a volatile hydrocarbon, for example 1 to 30% w/w.
  • formulations which are substantially free of volatile adjuvants are preferred.
  • the formulations of the invention are substantially free of liquid components of higher polarity than the propellant employed.
  • Polarity may be determined for example, by the method described in European Patent Application Publication No. 0327777.
  • formulations which are substantially free of alcohols such as ethanol are preferable.
  • substantially free means less than 1% w/w based upon the fluorocarbon or hydrogen-containing chlorofluorocarbon, in particular less than 0.5% for example 0.1% or less.
  • a particularly preferred embodiment the invention provides a pharmaceutical aerosol formulation consisting essentially of one more particulate medicament and one or more fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof.
  • the formulations of the invention may be prepared by dispersal of the medicament in the selected propellant in an appropriate container, e.g. with the aid of sonication.
  • the process is desirably carried out under anhydrous conditons to obviate any adverse effects of moisture on suspension stability.
  • the formulations according to the invention form weakly flocculated suspensions on standing but, surprisingly, these suspensions have been found to be easily redispersed by mild agitation to provide suspensions with excellent delivery characteristics suitable for use in pressurised inhalers, even after prolonged storage.
  • Minimising and preferably avoiding the use of formulation excipients e.g. surfactants, cosolvents etc in the aerosol formulations according to the invention is also advantageous since the formulations may be substantially taste and odour free, less irritant and less toxic than conventional formulations.
  • the chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations according to the invention may be determined by techniques well known to those skilled in the art.
  • the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product.
  • Physical stability data may be gained from other conventional analytical techniques such as, for example,- by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis.
  • the particle size distribution of the aerosol formulations according to the invention is particularly impressive and may be measured by conventional techniques, for example by cascade impaction or by the "Twin Impinger” analytical process.
  • Twin Impinger assay means "Determination of the deposition of the emitted dose in pressurised inhalations using apparatus A” as defined in British Pharmacopaeia 1988, pages A204-207, Appendix XVII C.
  • Such techniques enable the "respirable fraction" of the aerosol formulations to be calculated.
  • respirable fraction means the amount of active ingredient collected in the lower impingement chamber per actuation expressed as a percentage of the total amount of active ingredient delivered per actuation using the twin impinger method described above.
  • the formulations according to the invention have been found to have a respirable fraction of 20% or more by weight of the medicament, preferably 25 to 70%, for example 30 to
  • the medicament may be surface-modified prior to its dispersion in the propellant by treatment with a substantially non-polar liquid medium which is a non-solvent for the medicament.
  • a substantially non-polar liquid medium which is a non-solvent for the medicament.
  • surface-modified medicament particles of medicament which have been surface-modified by admixture with a substantially non-polar non-solvent liquid, followed by removal of the liquid, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof.
  • the substantially non-polar non-solvent liquid medium is conveniently an aliphatic hydrocarbon, e.g. a lower alkane, which is sufficiently volatile to permit its ready evaporation, e.g. at ambient temperature and pressure, after slurrying with the medicament.
  • isopentane as liquid medium is particularly advantageous in this respect.
  • the medicament is desirably slurried with' the liquid medium under anhydrous conditions to obviate any adverse effects of moisture on suspension stability.
  • the slurry may advantageously be sonicated to maximise the surface-modifying effect of the treatment.
  • the liquid may be removed by any convenient means for example by evaporation or by filtration followed by evaporation, provided that following treatment the medicament is substantially free of the liquid.
  • the formulations of the invention will be substantially free of the non-solvent non-polar liquid.
  • Surface-modified medicament prepared by the above described process comprises a further aspect of the present invention.
  • the formulations according to the invention may be filled into canisters suitable for delivering pharmaceutical aerosol formulations.
  • Canisters generally comprise a container capable of withstanding the vapour pressure of the propellant used such as a plastic or plastic-coated glass bottle or preferably a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve.
  • the metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve.
  • the gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene.
  • Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (e.g. DF10, DF30, DF60), Bespa pic, UK (e.g. BK300, BK356) and 3M-Neotechnic Ltd, UK (e.g. SpraymiserTM).
  • Each filled canister is conveniently fitted into a suitable channelling device prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient.
  • Suitable channelling devices comprise for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient e.g. a mouthpiece actuator.
  • Metered dose inhalers are designed to deliver a fixed unit dosage of medicament per actuation or "puff", for example in the range of 10 to 5000 microgram medicament per puff.
  • Administration of medicament may be indicated for the treatment of mild, moderate or severe acute or chronic symptoms or for prophylactic treatment. It will be appreciated that the precise dose administered will depend on the age and condition of the patient, the particular particulate medicament used and the frequency of administration and will ultimately be at the discretion of the attendant physician. When combinations of medicaments are employed the dose of each component of the combination will in general be that employed for each component when used alone. Typically, administration may be one or more times, for example from 1 to 8 times per day, giving for example 1,2,3 or 4 puffs each time.
  • each valve actuation may deliver 5mg sodium cromoglycate, 250 microgram terbutaline sulphate or 500 microgram reproterol hydrochloride.
  • each filled canister for use in a metered dose inhaler contains 100, 160 or 240 metered doses or puffs of medicament.
  • the filled canisters and metered dose inhalers described herein comprise further aspects of the present invention.
  • a still further aspect of the present invention comprises a method of treating respiratory disorders such as, for example, asthma, which comprises administration by inhalation of an effective amount of a formulation as herein described.
  • respiratory disorders such as, for example, asthma
  • administration by inhalation of an effective amount of a formulation as herein described serve to illustrate the invention.
  • Micronised sodium cromoglycate (1.2g) is weighed directly into an aluminium can and 1, 1,1,2-tetrafluorethane (to 18.2g) added from a vacuum flask. A metering valve is crimped into place and the sealed can sonicated for five minutes. The aerosol delivers 5mg sodium cromoglycate per actuation.
  • Micronised terbutaline sulphate (60mg) is weighed directly into an aluminium can and 1, 1, 1,2-tetrafluorethane (to 18.2g) added from a vacuum flask. A metering valve is crimped into place and the sealed can sonicated for five minutes. The aerosol delivers 250 microgram terbutaline sulphate per actuation.
  • Example 3
  • Micronised reproterol hydrochloride 120mg is weighed directly into an aluminium can and 1,1, 1 ,2-tetrafluorethane (to 18.2g) added from a vacuum flask. A metering valve is crimped into place and the sealed can sonicated for five minutes. The aerosol delivers 500 microgram reproterol hydrochloride per actuation.
  • Micronised terbutaline sulphate (60mg) is weighed directly into an aluminium can and I, l,l,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask. A metering valve is crimped into place and the sealed can sonicated for five minutes. The aerosol delivers 250 microgram terbutaline sulphate per actuation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant and with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

Description

MEDICAMENTS
This invention relates to aerosol formulations of use for the administration of medicaments by inhalation.
The use of aerosols to administer medicaments has been known for several decades. Such aerosols generally comprise the medicament, one or more chlorofluorocarbon propellants and either a surfactant or a solvent, such as ethanoi. The most commonly used aerosol propellants for medicaments have been propellant 1 1 (CC13F) and/or propellant 1 14 (CF2C1CF:C1) with propellant 12 (CC1,F2). However these propellants are now believed to provoke the degradation of stratospheric ozone and there is thus a need to provide aerosol formulations for medicaments which employ so called "ozone-friendly" propellants.
A class of propellants which are believed to have minimal ozone-depleting effects in comparison to conventional chlorofluorocarbons comprise fluorocarbons and hydrogen^containing chlorofluorocarbons, and a number of medicinal aerosol formulations using such propellant systems are disclosed in, for example, EP 0372777, WO91/0401 1, WO91/11 173, WO91/1 1495 and WO91/14422. These applications are all concerned with the preparation of pressurised aerosols for the administration of medicaments and seek to overcome the problems associated with the use of the new class of propellants, in particular the problems of stability associated with the pharmaceutical formulations prepared. The applications all propose the addition of one or more of adjuvants such as alcohols, alkanes, dimethyl ether, surfactants (including fluorinated and non-fluorinated surfactants, carboxylic acids, polyethoxylates etc) and even conventional chlorofluorocarbon propellants in small amounts intended to minimise potential ozone damage. Thus, for example EP 0372777 requires the use of 1 , 1 , 1 ,2-tetrafluoroethane in combination with both a cosolvent having greater polarity than 1, 1, 1,2-tetrafluoroethane
(e.g. an alcohol or a lower alkane) and a surfactant in order to achieve a stable formulation of a medicament powder. In particular it is noted in the specification at page 3, line 7 that "it has been found that the use of propellant 134a (1, 1, 1,2-tetrafluoroethane) and drug as a binary mixture or in combination with a conventional surfactant such as sorbitan trioleate does not provide formulations having suitable properties for use with pressurised inhalers". Surfactants are generally recognised by those skilled in the art to be essential components of aerosol formulations, required not only to reduce aggregation of the medicament but also to lubricate the valve employed, thereby ensuring consistent reproducibility of valve actuation and accuracy of dose dispensed. Whilst WO91/11173, WO91/11495 and WO91/14422 are concerned with formulations comprising an admixture of drug and surfactant, WO91/04011 discloses medicinal aerosol formulations in which the particulate medicaments are pre-coated with surfactant prior to dispersal in 1, 1, 1,2-tetrafluoroethane-
We have now 'surprisingly found that, in contradistinction to these teachings, it is in fact possible to obtain satisfactory dispersions of medicaments in fluorocarbon or hydrogen-containing chlorofluorocarbon propellants such as 1,1, 1,2-tetrafluoroethane without recourse to the use of any surfactant or cosolvent in the composition, or the necessity to pre-treat the medicament prior to dispersal in the propellant-
There is thus provided in one aspect of the invention a pharmaceutical aerosol formulation which comprises particulate medicament and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant and with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof. By "substantially free of surfactant" is meant formulations which contain no significant amounts of surfactant, for example less than 0.0001% by weight of the medicament. The particle size of the particulate (e.g. micronised) medicament should be such as to permit inhalation of substantially all of the medicament into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and preferably in the range 1-10 microns, e.g. 1-5 microns.
Medicaments which may be administered in aerosol formulations according to the invention include any drug useful in inhalation therapy which may be presented in a form which is substantially completely insoluble in the selected propellant. Appropriate medicaments may thus be selected from, for example, analgesics, e.g. codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; anti-infectives, e.g. 5 cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g. methapyrilene; anti-inflammatories, e.g. flunisolide, budesonide, tipredane or triamcinolone acetonide; antitussives, e.g. noscapine; bronchodilators, e.g. ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine,
10 tulobuterol, orciprenaline, or (-)-4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl) ethoxy] hexyl]amino]methyl]benzenemethanol; diuretics, e.g. amiloride; anticholinergics e.g. ipratropium, atropine or oxitropium; hormones, e.g. cortisone, hydrocortisone or prednisolone; xanthines e.g. aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, e.g. insulin or glucagon. It will be
■ ^ clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant. 0 Particularly preferred medicaments for administration using aerosol formulations in accordance with the invention include anti-allergies, bronchodilators and anti-inflammatory steroids of use in the treatment of respiratory disorders such as asthma by inhalation therapy, for example cromoglycate (e.g. the sodium salt), terbutaline (e.g. the sulphate salt), reproterol (e.g. the hydrochloride salt) or (-)-4-amino- -> 3,5-dichloro- -[[[6-[2-(2-pyridinyl)-ethoxy]hexyl]amino]methyl]benzenemethanol.
It will be appreciated by those skilled in the art that the aerosol formulations according to the invention may , if desired, contain a combination of two or more active ingredients. Aerosol compositions containing two active ingredients (in a conventional propellant system) are known, for example, for the treatment of respiratory disorders such 0 as asthma. Accordingly the present invention further provides aerosol formulations in accordance with the invention which contain two or more particulate medicaments. Medicaments may be selected from suitable combinations of the medicaments mentioned hereinbefore. Thus, suitable combinations of bronchodilatory agents include ephedrine 5 and theophylline, fenoterol and ipratropium, and isoetharine and phenylephrine aerosol formulations-
Preferred aerosol formulations in accordance with the invention comprise (a) an effective amount of a particulate bronchodilatory medicament (b) an effective amount of a particulate antiinflammatory, preferably a steroidal antiinflammatory medicament and (c) a 10 fluorocarbon or hydrogen - containing chlorofluorocarbon propellant with the proviso that said medicaments are other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof. Alternatively aerosol formulations may contain a bronchodilator such as isoprenaline in combination with an antiallergic such as cromoglycate (e.g. the sodium salt). '15 Combinations of isoprenaline and sodium cromoglycate are especially preferred.
The final aerosol formulation desirably contains 0.005-10% w/w, preferably 0.005-5% w/w, especially 0-01-l.O% w/w, of medicament relative to the total weight of the formulation.
The propellants for use in the invention may be any fluorocarbon or 20 hydrogen-containing chlorofluorocarbon or mixtures thereof having a sufficient vapour pressure to render them effective as propellants. Preferably the propellant will be a non-solvent for the medicament. Suitable propellants include, for example, Cwhydrogen-containing chlorofluorocarbons such as CH2C1F, CC1F2CHC1F, CF3CHCIF, CHF,CCIF,, CHC1FCHF,, CF3CH,C1 and CC1F2CH3; C hydrogen-containing 5 fluorocarbons such as CHF2CHF2, CF3CFL,F, CHF2CH3 and CF3CHFCF3; and perfluorocarbons such as CF3CF3 and CF3CF2CF3.
Where mixtures of the fluorocarbons or hydrogen-containing chlorofluorocarbons are employed they may be mixtures of the above identified compounds or mixtures, preferably binary mixtures, with other fluorocarbons or hydrogen-containing 0 chlorofluorocarbons for example CHC1F,, CH-.F, and CF3CFL-. Preferably a single fluorocarbon or hydrogen-containing chlorofluorocarbon is employed as the propellant. Particularly preferred as propellants are CMhydrogen-containing fluorocarbons such as 1,1, 1,2-tetrafluoroethane (CF3CH2F) and 1, 1, 1, 2,3,3, 3-heptafluoro-n-propane (CF3CHFCF3). It is desirable that the formulations of the invention contain no components which may provoke the degradation of stratospheric ozone. In particular it is desirable that the formulations are substantially free of chlorofluorocarbons such as CC13F, CC12F and CF3CC13.
The propellant may additionally contain a volatile adjuvant such as a saturated hydrocarbon for example propane, n-butane, isobutane, pentane and isopentane or a dialkyl ether for example dimethyl ether. In general, up to 50% w/w of the propellant may comprise a volatile hydrocarbon, for example 1 to 30% w/w. However, formulations which are substantially free of volatile adjuvants are preferred.
It is further desirable that the formulations of the invention are substantially free of liquid components of higher polarity than the propellant employed. Polarity may be determined for example, by the method described in European Patent Application Publication No. 0327777. In particular formulations which are substantially free of alcohols such as ethanol are preferable. As used herein "substantially free" means less than 1% w/w based upon the fluorocarbon or hydrogen-containing chlorofluorocarbon, in particular less than 0.5% for example 0.1% or less.
A particularly preferred embodiment the invention provides a pharmaceutical aerosol formulation consisting essentially of one more particulate medicament and one or more fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof.
The formulations of the invention may be prepared by dispersal of the medicament in the selected propellant in an appropriate container, e.g. with the aid of sonication. The process is desirably carried out under anhydrous conditons to obviate any adverse effects of moisture on suspension stability. The formulations according to the invention form weakly flocculated suspensions on standing but, surprisingly, these suspensions have been found to be easily redispersed by mild agitation to provide suspensions with excellent delivery characteristics suitable for use in pressurised inhalers, even after prolonged storage. Minimising and preferably avoiding the use of formulation excipients e.g. surfactants, cosolvents etc in the aerosol formulations according to the invention is also advantageous since the formulations may be substantially taste and odour free, less irritant and less toxic than conventional formulations.
The chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations according to the invention may be determined by techniques well known to those skilled in the art. Thus, for example, the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product. Physical stability data may be gained from other conventional analytical techniques such as, for example,- by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis.
The particle size distribution of the aerosol formulations according to the invention is particularly impressive and may be measured by conventional techniques, for example by cascade impaction or by the "Twin Impinger" analytical process. As used herein reference to the "Twin Impinger" assay means "Determination of the deposition of the emitted dose in pressurised inhalations using apparatus A" as defined in British Pharmacopaeia 1988, pages A204-207, Appendix XVII C. Such techniques enable the "respirable fraction" of the aerosol formulations to be calculated. As used herein reference to "respirable fraction" means the amount of active ingredient collected in the lower impingement chamber per actuation expressed as a percentage of the total amount of active ingredient delivered per actuation using the twin impinger method described above. The formulations according to the invention have been found to have a respirable fraction of 20% or more by weight of the medicament, preferably 25 to 70%, for example 30 to Optionally, the medicament may be surface-modified prior to its dispersion in the propellant by treatment with a substantially non-polar liquid medium which is a non-solvent for the medicament. There is thus provided in a further aspect of the invention an aerosol formulation comprising particulate, surface-modified medicament, as defined herein, and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. By "surface-modified medicament" is meant particles of medicament which have been surface-modified by admixture with a substantially non-polar non-solvent liquid, followed by removal of the liquid, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof. The substantially non-polar non-solvent liquid medium is conveniently an aliphatic hydrocarbon, e.g. a lower alkane, which is sufficiently volatile to permit its ready evaporation, e.g. at ambient temperature and pressure, after slurrying with the medicament. The use of isopentane as liquid medium is particularly advantageous in this respect.
The medicament is desirably slurried with' the liquid medium under anhydrous conditions to obviate any adverse effects of moisture on suspension stability. The slurry may advantageously be sonicated to maximise the surface-modifying effect of the treatment. The liquid may be removed by any convenient means for example by evaporation or by filtration followed by evaporation, provided that following treatment the medicament is substantially free of the liquid. The formulations of the invention will be substantially free of the non-solvent non-polar liquid. Surface-modified medicament prepared by the above described process comprises a further aspect of the present invention. The formulations according to the invention may be filled into canisters suitable for delivering pharmaceutical aerosol formulations. Canisters generally comprise a container capable of withstanding the vapour pressure of the propellant used such as a plastic or plastic-coated glass bottle or preferably a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve. The metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve. The gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (e.g. DF10, DF30, DF60), Bespa pic, UK (e.g. BK300, BK356) and 3M-Neotechnic Ltd, UK (e.g. Spraymiser™).
Conventional bulk manufacturing methods and machinery well known to those skilled in the art of pharmaceutical aerosol manufacture may be employed for the preparation of large scale batches for the commercial production of filled canisters. Thus, for example,, in one bulk manufacturing method a metering valve is crimped onto an aluminium can to form an empty canister. The particulate medicament is added to a charge vessel and liquified propellant is pressure filled through the charge vessel into a manufacturing vessel. The drug suspension is mixed before recirculation to a filling machine and an aliquot of the drug suspension is then filled through the metering valve into the canister. Typically, in batches prepared for pharmaceutical use, each filled canister is check-weighed, coded with a batch number and packed into a tray for storage before release testing.
Each filled canister is conveniently fitted into a suitable channelling device prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient. Suitable channelling devices comprise for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient e.g. a mouthpiece actuator. Metered dose inhalers are designed to deliver a fixed unit dosage of medicament per actuation or "puff", for example in the range of 10 to 5000 microgram medicament per puff.
Administration of medicament may be indicated for the treatment of mild, moderate or severe acute or chronic symptoms or for prophylactic treatment. It will be appreciated that the precise dose administered will depend on the age and condition of the patient, the particular particulate medicament used and the frequency of administration and will ultimately be at the discretion of the attendant physician. When combinations of medicaments are employed the dose of each component of the combination will in general be that employed for each component when used alone. Typically, administration may be one or more times, for example from 1 to 8 times per day, giving for example 1,2,3 or 4 puffs each time.
Thus, for example, each valve actuation may deliver 5mg sodium cromoglycate, 250 microgram terbutaline sulphate or 500 microgram reproterol hydrochloride. Typically each filled canister for use in a metered dose inhaler contains 100, 160 or 240 metered doses or puffs of medicament. The filled canisters and metered dose inhalers described herein comprise further aspects of the present invention.
A still further aspect of the present invention comprises a method of treating respiratory disorders such as, for example, asthma, which comprises administration by inhalation of an effective amount of a formulation as herein described. The following non-limitative Examples serve to illustrate the invention.
Example 1
Micronised sodium cromoglycate (1.2g) is weighed directly into an aluminium can and 1, 1,1,2-tetrafluorethane (to 18.2g) added from a vacuum flask. A metering valve is crimped into place and the sealed can sonicated for five minutes. The aerosol delivers 5mg sodium cromoglycate per actuation.
Example 2
Micronised terbutaline sulphate (60mg) is weighed directly into an aluminium can and 1, 1, 1,2-tetrafluorethane (to 18.2g) added from a vacuum flask. A metering valve is crimped into place and the sealed can sonicated for five minutes. The aerosol delivers 250 microgram terbutaline sulphate per actuation. Example 3
Micronised reproterol hydrochloride (120mg) is weighed directly into an aluminium can and 1,1, 1 ,2-tetrafluorethane (to 18.2g) added from a vacuum flask. A metering valve is crimped into place and the sealed can sonicated for five minutes. The aerosol delivers 500 microgram reproterol hydrochloride per actuation.
Example 4
Micronised terbutaline sulphate (60mg) is weighed directly into an aluminium can and I, l,l,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask. A metering valve is crimped into place and the sealed can sonicated for five minutes. The aerosol delivers 250 microgram terbutaline sulphate per actuation.

Claims

Claims
1. A pharmaceutical aerosol formulation which comprises particulate medicament and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation
5 is substantially free of surfactant and with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof.
2. A pharmaceutical aerosol formulation consisting essentially of one more particulate medicament and one or more fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof.
-■> 3. A formulation as claimed in Claim 1 or Claim 2 wherein said medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid.
4. A formulation as claimed in any one of Claims 1 to 3 wherein said medicament is cromoglycate, terbutaline, reproterol or (-)-4-amino-3,5-dichloro-α-[[[6-[2- 0 (2-pyridinyI)ethoxy]hexyl]amιno]methyl]benzenemethanol or a physiologically acceptable salt thereof.
5. A formulation as claimed in any one of claims 1 to 4 which contains two or more particulate medicaments. 5
6. A formulation as claimed in any one of claims 1 to 5 which comprises a particulate bronchodilatory medicament and a particulate anti-inflammatory medicament.
0
7. A formulation as claimed in any one of Claims 1 to 5 which comprises a particulate bronchodilatory medicament and a particulate anti-allergic medicament.
8. A formulation as claimed in Claim 7 which comprises isoprenaline and cromoglycate or a physiologically acceptable salt thereof.
9. A formulation as claimed in any one of Claims 1 to 8 which contains 0.005 to 10% w/w of medicament relative to the total weight of the formulation.
10. A formulation as claimed in any one of Claims I to 9 wherein the propellant is 1,1, 1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane.
11. A formulation as claimed in any one of Claims 1 to 10 which has a respirable fraction of 20% or more by weight of the medicament.
12. A formulation as claimed in any one of Claims 1 to 11 wherein said particulate medicament is surface-modified.
13. Surface-modified medicament prepared by admixture of particles of a medicament other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof, with a substantially non-polar, non-solvent liquid, followed by removal of the liquid.
14. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant and with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof.
15. A metered dose inhaler which comprises a canister as claimed in Claim 14 fitted into a suitable channelling device.
16. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation which comprises particulate medicament and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant and with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof.
PCT/EP1992/002809 1991-12-12 1992-12-04 Medicaments WO1993011744A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DK04007494T DK1440686T3 (en) 1991-12-12 1992-12-04 aerosol
AU30851/92A AU663905B2 (en) 1991-12-12 1992-12-04 Medicaments
JP5510574A JP3026841B2 (en) 1991-12-12 1992-12-04 Medicine
EP92924668A EP0616524B1 (en) 1991-12-12 1992-12-04 Medicaments
CA002125666A CA2125666C (en) 1991-12-12 1992-12-04 Medicaments
DK92924668T DK0616524T3 (en) 1991-12-12 1992-12-04 drugs
DE69227257T DE69227257T2 (en) 1991-12-12 1992-12-04 DRUG
US11/124,086 US20050207991A1 (en) 1991-12-12 2005-05-09 Aerosol formulations containing P134a and particulate medicament

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919126405A GB9126405D0 (en) 1991-12-12 1991-12-12 Medicaments
GB9126405.1 1991-12-12
GB9202522.0 1992-02-06
GB929202522A GB9202522D0 (en) 1992-02-06 1992-02-06 Medicaments

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08094175 A-371-Of-International 1993-08-05
US30243594A Continuation 1991-12-12 1994-09-09

Publications (1)

Publication Number Publication Date
WO1993011744A1 true WO1993011744A1 (en) 1993-06-24

Family

ID=26299997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1992/002809 WO1993011744A1 (en) 1991-12-12 1992-12-04 Medicaments

Country Status (10)

Country Link
US (6) US5922306A (en)
EP (1) EP0616524B1 (en)
JP (1) JP3026841B2 (en)
AT (1) ATE171865T1 (en)
AU (1) AU663905B2 (en)
CA (4) CA2125666C (en)
DE (1) DE69227257T2 (en)
DK (1) DK0616524T3 (en)
ES (1) ES2123576T3 (en)
WO (1) WO1993011744A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US5605674A (en) * 1988-12-06 1997-02-25 Riker Laboratories, Inc. Medicinal aerosol formulations
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5674472A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5817293A (en) * 1991-12-12 1998-10-06 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US6039974A (en) * 1997-08-26 2000-03-21 Hoechst Marion Roussel, Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6113942A (en) * 1995-02-28 2000-09-05 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
US6200549B1 (en) 1991-12-12 2001-03-13 Glaxo Group Limited Aerosol formulation containing P134a and particulate medicament
US6416743B1 (en) 1991-06-10 2002-07-09 Schering Corporation Aerosol formulations of albuterol and 1,1,1,2-tetrafluoroethane
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
US7090831B1 (en) 1999-04-14 2006-08-15 Smithkline Beecham Corporation Pharmaceutical aerosol formulation
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
JP2008285497A (en) * 1994-01-27 2008-11-27 Schering Corp Use of mometasone furoate for treating airway passage and lung disease
US7566445B1 (en) 1996-08-01 2009-07-28 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
WO2011049539A1 (en) * 2009-10-20 2011-04-28 Mahmut Bilgic Compositions comprising a corticosteroid, a beta2 agonist as well as cromoglicic acid or ndeocromil
US7977045B2 (en) 1996-07-03 2011-07-12 Aventis Pharmaceuticals Inc. Aqueous-based pharmaceutical composition
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US9616060B2 (en) 2002-04-17 2017-04-11 Nektar Therapeutics Particulate materials
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
ATE204743T1 (en) * 1991-12-18 2001-09-15 Minnesota Mining & Mfg AEROSOL COMPOSITIONS FOR MEDICINAL SUSPENSIONS
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
US6406745B1 (en) 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US7648696B2 (en) * 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
CA2383222C (en) * 1999-09-13 2008-11-18 Bridge Pharma, Inc. Optically active isomers of ketotifen and therapeutically active metabolites thereof
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030091513A1 (en) * 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20080118442A1 (en) * 2003-09-10 2008-05-22 Map Pharmaceuticals, Inc. Aerosol Formulations for Delivery of Dihydroergotamine to the Systemic Circulations Via Pulmonary Inhalation
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
WO2007011989A2 (en) * 2005-07-15 2007-01-25 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US20120204871A1 (en) 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
TWI399202B (en) 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004011A1 (en) * 1989-09-20 1991-04-04 Riker Laboratories, Inc. Medicinal aerosol formulations
WO1991011495A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Novel vehicle gas mixtures and their use in medical preparations
WO1991011173A1 (en) * 1990-02-02 1991-08-08 Fisons Plc Propellant compositions
WO1991014422A1 (en) * 1990-03-23 1991-10-03 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
WO1992008447A1 (en) * 1990-11-09 1992-05-29 Glaxo Group Limited Aerosol containing medicaments

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (en) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
BE556587A (en) * 1957-01-31 1957-04-11
BE629985A (en) * 1962-11-29
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3261748A (en) 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
US3348730A (en) * 1965-06-28 1967-10-24 Zumbiel C W Co Carriers for bottles and other articles
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3895111A (en) * 1973-06-27 1975-07-15 American Cyanamid Co Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
FI770215A (en) * 1976-01-30 1977-07-31 Fisons Ltd
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
NL7708731A (en) * 1976-08-13 1978-02-15 Montedison Spa PROCESS FOR THE PREPARATION OF NEW DRIVER COMPOSITIONS FOR AEROSOLS.
GB2088877B (en) 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
FI63672C (en) 1980-05-19 1983-08-10 Orion Yhtymae Oy FOERFARANDE FOER FRAMSTAELLNING AV EN BLANDNING AV BEKLOMETASONDIPROPIONAT OCH TRIKLORFLUORMETAN ELLER DIKLORDIFLUORMETAN
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
GB8820398D0 (en) 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
DE3905726A1 (en) 1989-02-24 1990-08-30 Hoechst Ag COMPRESSED GAS PACKING AND DRIVING AGENT FOR AEROSOLS
US4940171A (en) 1989-05-18 1990-07-10 Gilroy Gordon C Aerosol package having compressed gas propellant and vapor tap of minute size
GB2235627B (en) 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (en) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
IE912246A1 (en) 1990-06-28 1992-01-01 Glaxo Inc Aerosol drug formulations
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
SK392592A3 (en) 1990-06-29 1994-07-06 Fisons Plc Pressure aerosol composition
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
JP2769925B2 (en) 1990-10-18 1998-06-25 ミネソタ マイニング アンド マニュファクチャリング カンパニー Aerosol formulation comprising beclomethasone 17,21 dipropionate
GB9024365D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
EP0518601A1 (en) 1991-06-10 1992-12-16 Schering Corporation Non-chlorofluorocarbon aerosol formulations
ATE246497T1 (en) * 1991-06-10 2003-08-15 Schering Corp HYDROCHLOROFLUOROCARBON-FREE AEROSOL FORMULATIONS
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
EP0616525B1 (en) 1991-12-12 1995-09-27 Glaxo Group Limited Pharmaceutical aerosol formulation
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2125666C (en) * 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
ATE204743T1 (en) 1991-12-18 2001-09-15 Minnesota Mining & Mfg AEROSOL COMPOSITIONS FOR MEDICINAL SUSPENSIONS
US5202110A (en) 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5833950A (en) 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
EP0731688B1 (en) * 1993-12-02 2003-03-05 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
US6013245A (en) 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
GB9510750D0 (en) 1995-05-26 1995-07-19 Zeneca Ltd Chemical process
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004011A1 (en) * 1989-09-20 1991-04-04 Riker Laboratories, Inc. Medicinal aerosol formulations
WO1991011173A1 (en) * 1990-02-02 1991-08-08 Fisons Plc Propellant compositions
WO1991011495A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Novel vehicle gas mixtures and their use in medical preparations
WO1991014422A1 (en) * 1990-03-23 1991-10-03 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
WO1992008447A1 (en) * 1990-11-09 1992-05-29 Glaxo Group Limited Aerosol containing medicaments

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5605674A (en) * 1988-12-06 1997-02-25 Riker Laboratories, Inc. Medicinal aerosol formulations
US6352684B1 (en) 1988-12-06 2002-03-05 Riker Laboratories Inc. CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
US5674473A (en) * 1988-12-06 1997-10-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776434A (en) * 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5681545A (en) * 1988-12-06 1997-10-28 Riker Laboratories, Inc. Medicinal aerosol formulations
US5683677A (en) * 1988-12-06 1997-11-04 Riker Laboratories, Inc. Medicinal aerosol formulations
US5695743A (en) * 1988-12-06 1997-12-09 Riker Laboratories, Inc. Medicinal aerosol formulations
US5720940A (en) * 1988-12-06 1998-02-24 Riker Laboratories, Inc. Medicinal aerosol formulations
US6503482B1 (en) 1991-06-10 2003-01-07 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US6416743B1 (en) 1991-06-10 2002-07-09 Schering Corporation Aerosol formulations of albuterol and 1,1,1,2-tetrafluoroethane
US6306369B1 (en) 1991-12-12 2001-10-23 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US6893628B2 (en) 1991-12-12 2005-05-17 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5817293A (en) * 1991-12-12 1998-10-06 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US7498020B2 (en) 1991-12-12 2009-03-03 Glaxo Group Limited Medicaments
US6919069B2 (en) 1991-12-12 2005-07-19 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US6200549B1 (en) 1991-12-12 2001-03-13 Glaxo Group Limited Aerosol formulation containing P134a and particulate medicament
US6221339B1 (en) 1991-12-12 2001-04-24 Glaxo Group Limited Medicaments
US6238647B1 (en) 1991-12-12 2001-05-29 Glaxo Group Limited Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
US6251368B1 (en) 1991-12-12 2001-06-26 Glaxo Group Limited Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant
US6303103B1 (en) 1991-12-12 2001-10-16 Glaxo Group Limited Aerosols containing salmeterol xinafoate and an anticholinergic medicament
US5674472A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US6333023B1 (en) 1991-12-12 2001-12-25 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
JP2012036222A (en) * 1994-01-27 2012-02-23 Schering Corp Use of mometasone furoate for treating airway passage and lung diseases
JP2008285497A (en) * 1994-01-27 2008-11-27 Schering Corp Use of mometasone furoate for treating airway passage and lung disease
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US8129408B2 (en) 1995-02-28 2012-03-06 Aventisub Ii Inc. Pharmaceutical composition for piperidinoalkanol compounds
US6113942A (en) * 1995-02-28 2000-09-05 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US7977045B2 (en) 1996-07-03 2011-07-12 Aventis Pharmaceuticals Inc. Aqueous-based pharmaceutical composition
US8834849B2 (en) 1996-08-01 2014-09-16 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US7566445B1 (en) 1996-08-01 2009-07-28 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US9650203B2 (en) 1996-08-01 2017-05-16 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US6039974A (en) * 1997-08-26 2000-03-21 Hoechst Marion Roussel, Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US7090831B1 (en) 1999-04-14 2006-08-15 Smithkline Beecham Corporation Pharmaceutical aerosol formulation
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9616060B2 (en) 2002-04-17 2017-04-11 Nektar Therapeutics Particulate materials
US10251881B2 (en) 2002-04-17 2019-04-09 Nektar Therapeutics Particulate materials
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US10172853B2 (en) 2007-02-11 2019-01-08 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
WO2011049539A1 (en) * 2009-10-20 2011-04-28 Mahmut Bilgic Compositions comprising a corticosteroid, a beta2 agonist as well as cromoglicic acid or ndeocromil

Also Published As

Publication number Publication date
EP0616524B1 (en) 1998-10-07
US20050207991A1 (en) 2005-09-22
CA2125666C (en) 2002-07-16
JPH07502034A (en) 1995-03-02
CA2421976C (en) 2004-04-20
US20020031479A1 (en) 2002-03-14
US5922306A (en) 1999-07-13
CA2125666A1 (en) 1993-06-24
EP0616524A1 (en) 1994-09-28
US6893628B2 (en) 2005-05-17
DE69227257D1 (en) 1998-11-12
US20030165437A1 (en) 2003-09-04
US6306369B1 (en) 2001-10-23
CA2381329A1 (en) 1993-06-24
CA2381329C (en) 2003-04-15
DE69227257T2 (en) 1999-03-25
CA2455115A1 (en) 1993-06-24
US6200549B1 (en) 2001-03-13
CA2455115C (en) 2008-05-27
DK0616524T3 (en) 1999-06-21
AU3085192A (en) 1993-07-19
ES2123576T3 (en) 1999-01-16
ATE171865T1 (en) 1998-10-15
JP3026841B2 (en) 2000-03-27
AU663905B2 (en) 1995-10-26
CA2421976A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
US5744123A (en) Aerosol formulations containing P134a and particulate medicaments
US5922306A (en) Aerosol formulations containing P134a and particulate medicament
US5736124A (en) Aerosol formulations containing P134a and particulate medicament
US5817293A (en) Canister containing aerosol formulations containing P134a and particulate medicaments
US5653962A (en) Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) Aerosol formulations containing P134a and salbutamol
US5674472A (en) Canisters containing aerosol formulations containing P134a and fluticasone propionate
US5658549A (en) Aerosol formulations containing propellant 134a and fluticasone propionate
US6919069B2 (en) Aerosol formulation containing particulate formoterol, propellant and polar cosolvent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 1993 94175

Country of ref document: US

Date of ref document: 19930929

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1992924668

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2125666

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1992924668

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1992924668

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992924668

Country of ref document: EP